The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, 807-8555, Japan.
Curr Rheumatol Rep. 2019 Mar 20;21(5):21. doi: 10.1007/s11926-019-0817-x.
This review describes previously reported findings on optimal biologic agent selection for psoriatic arthritis (PsA) treatment and outlines our approach to developing precision medicine techniques for targeted treatment of this disease.
Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA. Although several studies have suggested specific predictors of treatment responses to each biologic, how biologics are differentially chosen in each patient remains unclear. Recent reports indicate the possibility of treating PsA using precision medicine based on individual immunological phenotypes. Because PsA exhibits numerous symptoms, selecting an optimal biologic for each patient may be important. The establishment of appropriate selection guidelines will require further clinical trials.
本文描述了既往关于治疗银屑病关节炎（PsA）的最佳生物制剂选择的报道，并概述了我们开发针对该疾病的精准医疗技术的方法。
临床试验已经报道了许多具有不同靶点的生物制剂的有效性，例如肿瘤坏死因子-α、白细胞介素（IL）-17A、IL-17 受体、IL-12/23（p40）和 IL-23（p19），用于治疗 PsA。尽管有几项研究表明了每种生物制剂治疗反应的特定预测因子，但在每个患者中如何选择生物制剂仍不清楚。最近的报告表明，基于个体免疫表型，使用精准医学治疗 PsA 是可能的。由于 PsA 表现出许多症状，为每个患者选择最佳的生物制剂可能很重要。建立适当的选择指南需要进一步的临床试验。
